Disease control: 21% PR; 47% SD; median PFS 17.1 monthsImmune response responders saw increased CD8+ TILs and CD8+ aggregates at tumour edge; non-responders saw no increase in CD8+ TILs or aggregates. Here, CD8A is linked to neoplasm.